NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma Inc (NASDAQ:ALBO) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.55) by $0.18. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analysts' expectations of $1.38 million. Albireo Pharma had a negative return on equity of 62.69% and a negative net margin of 1,881.86%. View Albireo Pharma's Earnings History.

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

4 Wall Street analysts have issued twelve-month price objectives for Albireo Pharma's shares. Their forecasts range from $39.00 to $69.00. On average, they anticipate Albireo Pharma's share price to reach $56.67 in the next twelve months. This suggests a possible upside of 126.9% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

News stories about ALBO stock have been trending very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Albireo Pharma earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Albireo Pharma.

Albireo Pharma saw a increase in short interest in December. As of December 31st, there was short interest totalling 791,600 shares, an increase of 6.0% from the December 15th total of 746,900 shares. Based on an average daily trading volume, of 72,500 shares, the short-interest ratio is presently 10.9 days. Currently, 7.8% of the shares of the stock are sold short. View Albireo Pharma's Current Options Chain.

Some companies that are related to Albireo Pharma include Myovant Sciences (MYOV), Endonovo Therapeutics (ENDV), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), NextCure (NXTC), Athenex (ATNX), Karyopharm Therapeutics (KPTI), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM) and IGM Biosciences (IGMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), CBL & Associates Properties (CBL), Cornerstone Total Return Fund (CRF), GW Pharmaceuticals PLC- (GWPH), Martin Midstream Partners (MMLP), Palatin Technologies (PTN), Exelixis (EXEL), Viking Therapeutics (VKTX) and SandRidge Permian Trust (PER).

Albireo Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Chicago Capital LLC (1.38%) and Alpine Global Management LLC (0.10%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Life Sciences Maste Perceptive, Phase4 Partners Ltd, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC. View Insider Buying and Selling for Albireo Pharma.

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $24.97.

Albireo Pharma has a market capitalization of $316.87 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-46,110,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.View Additional Information About Albireo Pharma.

The official website for Albireo Pharma is http://www.albireopharma.com/.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]